FDA Needs New Regulatory Model In Face Of Globalization, Woodcock Says
This article was originally published in PharmAsia News
Executive Summary
The FDA requires a new regulatory model to confront issues presented by globalization, which will include reliance on foreign regulators, according to agency Chief Medical Officer Janet Woodcock
You may also be interested in...
U.S. FDA Move “Beyond Our Borders” Begins With China
Congressional concerns over inspection oversight in the midst of a heparin safety scare have not dampened FDA's efforts to highlight its new overseas initiative, "FDA Beyond Our Borders.
U.S. FDA Move “Beyond Our Borders” Begins With China
Congressional concerns over inspection oversight in the midst of a heparin safety scare have not dampened FDA's efforts to highlight its new overseas initiative, "FDA Beyond Our Borders.
India Ready For Chemistry Outsourcing, Wyeth Says; Biology Remains In West
India is currently a viable option for simple chemistry outsourcing and offshoring; however, additional skill development is needed before medicinal chemistry and biology operations can be conducted there, speakers said at the Financial Times Global Pharmaceuticals & Biotechnology conference in London Sept. 18